Niraparib Combined With Radiotherapy in rGBM

Recurrent Glioblastoma Clinical Trial

Official title:

Efficacy and Safety of Niraparib Combined With Radiotherapy in Patients With Recurrent Glioblastoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04715620
• Other study ID #: TJHH-2306
• Status: Recruiting
• Phase: Phase 2
• Start date: January 2021
• Est. completion date: January 2023

Study information

• Verified date: January 2021
• Source: Tianjin Huanhu Hospital
• Contact: Wei Jiang
• Phone: +86 22 59065906
• Email: wjianghh[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Thirty patients were enrolled in this study, mainly patients with first recurrence of glioblastoma, and the requirement is that they can receive secondary radiotherapy. Regardless of whether the patient has received a second operation or the MGMT promoter is methylated, they can be included in this study. After enrollment, patients were given niraparib 300mg/day (body weight ≥77Kg and baseline platelet count ≥150,000/µL) or 200mg/day (body weight <77Kg or baseline platelet count <150,000/µL), combined with radiotherapy (total dose 55Gy), follow-up Time 1 year. Until the patient has disease progression or intolerance or voluntarily withdraw from the study.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: January 2023
• Est. primary completion date: January 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Sign a written informed consent form before conducting any research related procedures;

• Male or female aged between 18 and 70;

• Histologically confirmed WHO classification of recurrent glioblastoma grade IV;

• The expected survival time is more than 6 months

• Able to receive radiotherapy again

• KPS=60

• Can swallow and maintain oral medication

• In the past month, no more than 3 grand epileptic seizures per week

• Good organ function, including: Bone marrow function: neutrophil count =1500/µL; platelets =100,000/µL; hemoglobin =10g/dL; Liver function: total bilirubin =1.5 times the upper limit of normal or direct bilirubin =1.0 times the upper limit of normal; AST and ALT =2.5 times the upper limit of normal; Renal function: serum creatinine =1.5 times the upper limit of normal value, or creatinine clearance =60mL/min (calculated according to Cockcroft-Gault formula);

• Ability to follow the plan;

• Any previous toxicity of chemotherapy has returned to = CTCAE level 1 or baseline level, except for sensory neuropathy or alopecia with stable symptoms = CTCAE level 2.

Exclusion Criteria:

• Those who are known to be allergic to niraparib or the active or inactive ingredients of drugs with similar chemical structure to niraparib;

• Those who have previously received PARP inhibitor therapy;

• Have received major surgery within 3 weeks before the start of the study, or any surgical effects that have not recovered after surgery or received chemotherapy;

• Received palliative radiotherapy with> 20% bone marrow 1 week before enrollment;

• The patient has previously or currently diagnosed myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML);

• Suffer from serious or uncontrolled diseases, including but not limited to:

Uncontrollable nausea and vomiting, inability to swallow study drugs, any gastrointestinal diseases that may interfere with drug absorption and metabolism; active viral infections such as human immunodeficiency virus, hepatitis B, hepatitis C, etc.; uncontrolled ventricular Arrhythmia, myocardial infarction in the last 3 months; uncontrolled grand mal seizures, unstable spinal cord compression, superior vena cava syndrome, or other mental disorders that affect the patient's informed consent; immunodeficiency (except splenectomy) Or other researchers believe that it may expose patients to high-risk toxic diseases; hypertension that cannot be controlled by drugs; and manifestations of intracranial hypertension, intracranial hemorrhage, and intracranial infarction caused by any reason;

• Patients with distant metastasis;

• Any past or current disease, treatment, or laboratory abnormality that may interfere with the results of the study, affect the patient's full participation in the study, or the investigator believes that the patient is not suitable for participating in the study; the patient must not be allowed within four weeks before the start of the study drug treatment Receive platelet or red blood cell transfusion.

Related Conditions & MeSH terms

• Glioblastoma
• Recurrent Glioblastoma

Intervention

Drug:
• Niraparib
Niraparib 300mg/day (body weight =77Kg and baseline platelet count =150,000/µL) or 200mg/day (body weight <77Kg or baseline platelet count <150,000/µL)

Locations

Country	Name	City	State
China	Tianjin Huanhu Hosptal	Tianjin	Tianjin

Sponsors (1)

Lead Sponsor	Collaborator
Tianjin Huanhu Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	PFS-6	6-month progression-free survival rate	6 months